Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union

CAMBRIDGE, Massachusetts, June 25, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announced today that the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency adopted a
positive opinion on the marketing authorisation for VPRIV(TM) (velaglucerase
alfa), the company's enzyme replacement therapy (ERT) for the treatment of
type 1 Gaucher disease. The CHMP positive opinion will now be forwarded to
the European Commission for ratification, and marks a significant milestone
in bringing a new Gaucher treatment to market in all EU Member States.

"Gaucher disease is a rare and often debilitating condition," said
Professor Timothy Cox, Department of Medicine, University of Cambridge based
at Addenbrookes Hospital UK. "I am pleased that, given the difficulties in
supplying enzyme treatment for our patients over the last year, we will soon
have the opportunity to prescribe velaglucerase alfa without regulatory
constraints; the treatment represents an important option in this therapeutic
arena."

In many European countries patients have been receiving VPRIV on an early
access named patient basis, developed in partnership with national and
regional authorities. These programs, designed specifically to address the
continuing supply shortage of the only other commercially marketed ERT, have
experienced strong uptake from physicians and patients and have garnered the
support of treatment working groups and advocacy organisations. To date,
hundreds of patients in the EU have been treated with VPRIV through Shire's
clinical trials or early access mechanisms.

"A positive opinion for VPRIV in the EU, earlier than expected, is very
good news, particularly as we have been working with physicians in 22
countries for almost a year to treat patients with type 1 Gaucher disease
through early access programs," said Sylvie Gregoire, President, Shire Human
Genetic Therapies. "We look forward to our ongoing collaboration with these
physicians and the Gaucher community at large as we enter the final stages of
the approval process in Europe."

In addition to the CHMP positive opinion, VPRIV has received orphan drug
designation from the Committee for Orphan Medical Products.

With the accelerated adoption of VPRIV worldwide, and the earlier than
anticipated US approval and EU positive opinion, Shire expects continued high
demand for the therapy. As a result of this, the company is now implementing
a program with physicians and patients to monitor and manage requests from
new patients carefully in order to ensure long-term, uninterrupted treatment
with VPRIV.

Shire's VPRIV clinical development program represents the largest and
most comprehensive clinical data set supporting registration for an ERT for
Type 1 Gaucher disease to date.

About VPRIV(TM)

VPRIV is made using Shire's gene-activation technology, in a human cell
line. The glucocerebrosidase enzyme produced has the exact human amino acid
sequence and has a human glycosylation pattern.

VPRIV was approved by the U.S. Food and Drug Administration on February
26, 2010. For full US prescribing information see www.Vpriv.com.

Important Safety Information

The most serious adverse reactions in patients treated with VPRIV were
hypersensitivity reactions.

Infusion-related reactions were the most commonly observed adverse
reactions in patients treated with VPRIV in clinical studies. The most
commonly observed symptoms of infusion-related reactions were: headache,
dizziness, hypotension, hypertension, nausea, fatigue/asthenia, and pyrexia.
Generally the infusion-related reactions were mild and, in treatment-naive
patients, onset occurred mostly during the first 6 months of treatment and
tended to occur less frequently with time. Other commonly observed adverse
reactions in [greater than or equal to]10% of patients were: abdominal pain,
back pain, joint pain, upper respiratory tract infection, and activated
partial thromboplastin time prolonged. Adverse reactions more commonly seen
in pediatric patients (>10% difference) included upper respiratory tract
infection, rash, activated partial thromboplastin time prolonged, and
pyrexia.

In clinical trials one patient developed neutralizing antibodies.

About Gaucher Disease

Gaucher disease is an autosomal recessive disorder caused by mutations
in the GBA gene which results in a deficiency of the lysosomal enzyme
beta-glucocerebrosidase. This enzymatic deficiency causes an accumulation of
glucocerebroside, primarily in macrophages. In this lysosomal storage
disorder, clinical features are reflective of the distribution of Gaucher
cells in the liver, spleen, bone marrow, and other organs. The accumulation
of glucocerebroside in the liver and spleen leads to organomegaly. Presence
of Gaucher cells in the bone marrow and spleen lead to clinically significant
anemia and thrombocytopenia.

Gaucher disease is the most prevalent of the lysosomal storage disorders.
Gaucher disease has classically been categorized into 3 clinical types. Type
1 Gaucher disease is characterized by variability in signs, symptoms,
severity, and progression. Type 1 is the most common and is distinguished
from type 2 and type 3 by the lack of early neurological symptoms.

Note to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit hyperactivity
disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)
diseases as well as opportunities in other therapeutic areas to the extent
they arise through acquisitions. Shire's in-licensing, merger and acquisition
efforts are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes that a
carefully selected and balanced portfolio of products with strategically
aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the company's website:
www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number
of risks and uncertainties and are subject to change at any time. In the
event such risks or uncertainties materialize, the company's results could be
materially adversely affected. The risks and uncertainties include, but are
not limited to, risks associated with: the inherent uncertainty of research,
development, approval, reimbursement, manufacturing and commercialization of
the company's Specialty Pharmaceutical and Human Genetic Therapies products,
as well as the ability to secure and integrate new products for
commercialization and/or development; government regulation of the company's
products; the company's ability to manufacture its products in sufficient
quantities to meet demand; the impact of competitive therapies on the
company's products; the company's ability to register, maintain and enforce
patents and other intellectual property rights relating to its products; the
company's ability to obtain and maintain government and other third-party
reimbursement for its products; and other risks and uncertainties detailed
from time to time in the company's filings with the Securities and Exchange
Commission.

    For further information please contact:

    Investor Relations:

    Clea Rosenfeld (Rest of the World), +44-1256-894-160;
    Eric Rojas (North America), +1-617-551-9715.

    Media:

    Jessica Mann (Rest of the World), +44-1256-894-280;
    Jessica Cotrone (North America, HGT), +1-781-482-9538.

Investor Relations: Clea Rosenfeld (Rest of the World), +44-1256-894-160; Eric Rojas (North America), +1-617-551-9715. Media: Jessica Mann (Rest of the World), +44-1256-894-280; Jessica Cotrone (North America, HGT), +1-781-482-9538.